Photo: Eli Lilly and Company
The English High Court has ruled that a patent covering vitamin dosage regimens for Eli Lilly’s lung cancer drug Alimta (pemetrexed disodium) would not be infringed by generic competitors.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Alimta, Actavis, English High Court, dosage regimen patent